STAAR Surgical (NASDAQ:STAA) Raised to Strong-Buy at Zacks Research

STAAR Surgical (NASDAQ:STAA) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus raised their target price on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a report on Thursday, May 14th. Piper Sandler increased their price target on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Mizuho raised their price target on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Wells Fargo & Company raised their price target on STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. Finally, Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of STAAR Surgical in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $26.94.

STAAR Surgical Stock Performance

Shares of STAA opened at $22.86 on Tuesday. The stock has a market capitalization of $1.14 billion, a PE ratio of -53.16 and a beta of 1.26. The business’s fifty day moving average price is $27.43 and its 200 day moving average price is $23.95. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.12 and a quick ratio of 4.31. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The company had revenue of $93.52 million for the quarter, compared to analysts’ expectations of $78.72 million. During the same period in the prior year, the company earned ($1.10) earnings per share. The firm’s revenue was up 119.6% compared to the same quarter last year. Equities research analysts forecast that STAAR Surgical will post 0.13 EPS for the current year.

Institutional Trading of STAAR Surgical

Hedge funds have recently bought and sold shares of the company. Tudor Investment Corp ET AL bought a new position in STAAR Surgical in the 3rd quarter worth about $4,113,000. GSA Capital Partners LLP acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $910,000. UBS Group AG raised its holdings in shares of STAAR Surgical by 39.2% during the fourth quarter. UBS Group AG now owns 327,852 shares of the medical instruments supplier’s stock valued at $7,570,000 after buying an additional 92,321 shares during the last quarter. American Capital Management Inc. raised its holdings in shares of STAAR Surgical by 18.7% during the first quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier’s stock valued at $16,419,000 after buying an additional 138,499 shares during the last quarter. Finally, Crcm LP acquired a new position in shares of STAAR Surgical during the first quarter worth approximately $1,870,000. 96.70% of the stock is currently owned by institutional investors.

More STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Wedbush maintained its “Outperform” rating and set a $40 price target, implying substantial upside from the stock’s recent level. The bullish view may reflect confidence in STAAR Surgical’s earnings growth and demand for its implantable contact lenses. Benzinga analyst rating report
• Positive Sentiment: Zacks upgraded STAAR Surgical to Rank #1, or “Strong Buy,” citing improving earnings prospects. The upgrade could attract momentum-oriented investors and provide near-term support for STAA. Zacks Strong Buy upgrade
• Positive Sentiment: Warren Foust has been named president and chief executive officer. Foust previously served as STAAR Surgical’s chief operating officer and has experience at Johnson & Johnson, suggesting leadership continuity along with relevant industry expertise. Warren Foust named president and CEO STAAR Surgical appoints new CEO
• Neutral Sentiment: STAAR Surgical will release second-quarter 2026 results on August 12. The upcoming earnings call is the next major catalyst, with investors likely focused on procedure growth, sales momentum, margins and management’s outlook. STAAR Surgical second-quarter earnings call announcement
• Neutral Sentiment: Analysts collectively rate STAA “Hold.” This consensus is less bullish than the latest Zacks and Wedbush calls, indicating that valuation, execution or upcoming earnings risks remain concerns. STAAR Surgical analyst consensus

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.